MetLife Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Adjusted Earnings: $1.6 billion, or $2.34 per share (up 21% year-over-year), with notable items totaling $18 million or $0.03 per share.

Variable Investment Income: $483 million, exceeding the $425 million guidance, driven by strong private equity returns (3% for the quarter).

Adjusted Return on Equity: 16.7%, aligning with the target range of 15% to 17%.

Direct Expense Ratio: 11.6%, below the full-year target of 12.1%.

Shareholder Returns: Approximately $875 million returned through dividends and share repurchases in Q3, with year-to-date buybacks totaling $2.6 billion.

2Strategic Updates and Business Highlights

New Frontier Strategy: The strategy is showing positive results, particularly in Group Benefits, Retirement, and Asia.

Group Benefits: Adjusted earnings of $457 million (up 6%), driven by improved underwriting results and seasonal profitability in dental.

Retirement and Income Solutions (RIS): Adjusted earnings of $423 million (up 15%), with strong growth in structured settlements and U.K. longevity reinsurance.

Asia Performance: Adjusted earnings of $473 million (up 36%), with sales growth of 34% on a constant currency basis, particularly strong in Japan (31% increase).

Latin America: Adjusted earnings of $222 million (up 2%), with continued business momentum and partnerships, such as with MercadoLibre.

Chariot Re Launch: A new reinsurance initiative aimed at enhancing retirement liability origination capacity.

3Forward Guidance and Outlook

Pension Risk Transfer (PRT): Anticipated to be a record quarter with $12 billion already written in Q4, indicating strong market trust.

Expense Management: Expected to remain below the 12.1% target for the full year, aided by technology investments and operational efficiencies.

Long-term Growth: Positive outlook for PRT business with 94% of pension plan sponsors planning to derisk portfolios in the next five years.

4Bad News, Challenges, or Points of Concern

Tax Law Changes in Mexico: A notable charge of $71 million related to VAT deductions affecting health insurance claims, expected to impact earnings by $50-$60 million in 2026.

Group Benefits Underwriting: The group life mortality ratio was below target at 83.3%, raising concerns about future profitability.

Market Competition: The competitive environment remains rational but poses ongoing challenges for pricing and growth in Group Benefits.

5Notable Q&A Insights

Asia Sales Momentum: Continued strong performance attributed to new product launches and enhancements, with expectations to exceed full-year sales guidance.

PRT Competitive Landscape: Emphasis on MetLife's strengths in the jumbo market, highlighting financial strength and disciplined risk management as key competitive advantages.

Expense Seasonality: Anticipated higher expenses in Q4 but still below the full-year target, with technology investments contributing to efficiency gains.

Long-Term Care (LTC) Market: MetLife remains disciplined in exploring risk transfer opportunities while maintaining a well-capitalized and managed book of business. Overall, MetLife's Q3 2025 results reflect strong financial performance, strategic growth initiatives, and a positive outlook, tempered by some challenges in specific markets and regulatory environments.